Related Experiment Video
Updated: Jun 28, 2026
06:20
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
[Anticancer drug dose individualisation: from body surface area to physiology]
Aurélie Pétain1, Etienne Chatelut
1Institut Claudius-Regaud et EA3035, Université de Toulouse, 20, rue du Pont-Saint-Pierre, 31052 Toulouse cedex, France.
Bulletin Du Cancer
|November 14, 2008
Summary
Standard anticancer drug dosing based on body surface area is often inaccurate. Plasma drug concentrations correlate better with effects and toxicity, suggesting personalized dosing strategies are needed for better oncology outcomes.
Area of Science:
- Pharmacology
- Oncology
- Pharmacokinetics
Background:
- Anticancer drug doses are typically calculated using body surface area (BSA).
- This dosing method assumes drug clearance is proportional to BSA, which is often inaccurate.
- This can lead to suboptimal therapeutic effects and increased toxicity.
Purpose of the Study:
- To discuss the elimination pathways of anticancer drugs and their variability.
- To review methods for estimating renal function.
- To explore pharmacokinetic principles for individualized cancer drug dosing.
Main Methods:
- Review of anticancer drug elimination pathways and interindividual variability.
- Discussion of methods for assessing renal function.
- Application of pharmacokinetic concepts to individualize dosing.
Main Results:
- Drug clearance is frequently not proportional to body surface area.
- Plasma drug concentrations often correlate better with pharmacodynamic effects, including hematological toxicity, than with BSA-based doses.
- Individual variability in drug elimination impacts treatment efficacy and safety.
Conclusions:
- Relying solely on body surface area for anticancer drug dosing is suboptimal.
- Understanding drug pharmacokinetics and individual variability is crucial for optimizing cancer therapy.
- Pharmacokinetic principles enable the development of personalized dosing strategies in oncology.
More Related Videos
Related Concept Videos
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...